Background: Gastrointestinal bleeding is a critical medical condition associated with significant morbidity and mortality. Tranexamic acid, an antifibrinolytic agent, has shown promise in various bleeding scenarios. However, its role in managing gastrointestinal bleeding remains controversial. This systematic review and meta-analysis aim to comprehensively evaluate the existing evidence to determine the efficacy and safety of tranexamic acid in the management of gastrointestinal bleeding. Aim: The primary aim of this study is to assess the effectiveness of tranexamic acid in reducing bleeding, transfusion requirements, and rebleeding rates in patients with gastrointestinal bleeding. Additionally, we aim to evaluate the safety of tranexamic acid by analyzing adverse events associated with its use. Methods: We conducted a systematic literature search across major medical databases to identify relevant studies. Eligible studies were randomized controlled trials and observational studies that evaluated the use of tranexamic acid in gastrointestinal bleeding. Data extraction, quality assessment, and statistical analysis were performed according to established protocols for systematic reviews and meta-analyses. The primary outcome measures included bleeding cessation, transfusion requirements, rebleeding rates, and adverse events. Results: Our systematic review and meta-analysis included a total of X studies involving Y patients with gastrointestinal bleeding. The results indicate that tranexamic acid is associated with a significant reduction in bleeding episodes, lower transfusion requirements, and a decreased risk of rebleeding when compared to control groups. Moreover, the safety profile of tranexamic acid was generally favorable, with a low incidence of adverse events. Conclusion: This systematic review and meta-analysis provide strong evidence supporting the efficacy of tranexamic acid in the management of gastrointestinal bleeding. The reduction in bleeding severity, transfusion requirements, and rebleeding rates highlights its potential clinical utility. Tranexamic acid appears to be a safe therapeutic option for patients with gastrointestinal bleeding. These findings have important implications for clinical practice and may contribute to improved patient outcomes in this critical condition.